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Arteriolar hyalinosis is a common histological finding in renal
transplant recipients treated with the calcineurin inhibitor
tacrolimus; however, the pathophysiologic mechanisms
remain unknown. In addition to increasing transforming
growth factor (TGF)-b levels, tacrolimus inhibits calcineurin
by binding to FK506-binding protein 12 (FKBP12). FKBP12
alone also inhibits TGF-b receptor activation. Here we tested
whether tacrolimus binding to FKBP12 removes an inhibition
of the TGF-b receptor, allowing ligand binding, ultimately
leading to receptor activation and arteriolar hyalinosis. We
found that specific deletion of FKBP12 from endothelial cells
was sufficient to activate endothelial TGF-b receptors and
induce renal arteriolar hyalinosis in these knockout mice,
similar to that induced by tacrolimus. Tacrolimus-treated and
knockout mice exhibited significantly increased levels of
aortic TGF-b receptor activation as evidenced by SMAD2/3
phosphorylation, along with increased collagen and
fibronectin expression compared to controls. Treatment of
isolated mouse aortas with tacrolimus increased TGF-b
receptor activation and collagen and fibronectin expression.
These effects were independent of calcineurin, absent in
endothelial denuded aortic rings, and could be prevented by
the small molecule TGF-b receptor inhibitor SB-505124. Thus,
endothelial cell TGF-b receptor activation is sufficient to
cause vascular remodeling and renal arteriolar hyalinosis.
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Renal arteriolar hyalinosis is a cardinal feature of calcineurin
inhibitor toxicity, which is one of the leading causes of
chronic allograft nephropathy in transplant recipients.
Clinical studies have demonstrated a significant correlation
between the degree of arteriolar hyalinosis and dosage of the
calcineurin inhibitors tacrolimus (TAC) and ciclosporin,
as well as the duration of exposure.1,2 By 10 years post
transplant, 100% of renal and renal–pancreas allograft
recipients exhibit arteriolar hyalinosis.2,3 Evidence of this
vasculopathy may indicate progression toward chronic
allograft nephropathy and has been suggested to be more
important than tubular atrophy or interstitial fibrosis in the
progression toward renal injury.4 Although an association
between severity of hyalinosis and graft loss has not been
demonstrated,5 arteriolar hyalinosis is often associated with
renal dysfunction and the development of glomerulosclero-
sis.1–4,6 Despite the almost universal presence and predictive
nature of this arteriolopathy in allograft recipients, little is
known about how arteriolar hyalinosis develops during
calcineurin inhibitor therapy.
Arteriolar hyalinosis consists of the deposition of hyaline
into the vascular wall coupled with matrix protein synthesis
and is evident in other diseases including hypertension and
diabetes. Vascular matrix proteins such as collagen type I and
IV and fibronectin are increased in patients and animals
exhibiting arteriolar hyalinosis, and probably have a major
pathogenetic role.7,8 Arteriolar hyalinization alone may lead
to a conduit vessel-like structure resulting in reduced smooth
muscle contractility and loss of autoregulation.4 Experimen-
tal and clinical studies have implicated transforming growth
factor (TGF)-b1 as the primary initiator of arteriolar
hyalinosis, with angiotensin II also having a role.6–10 TGF-
b1 is a pleiotropic cytokine and primarily functions as an
anti-inflammatory and pro-fibrotic molecule. Calcineurin
inhibitors markedly increase TGF-b1 levels in humans and
animals, and neutralizing antibodies against TGF-b1 reduce
the degree of arteriolar hyalinosis and collagen expression in
kidneys from ciclosporin-treated rats.8,11–13 However, TGF-
b1 exerts both receptor-dependent and receptor-independent
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effects. Whether or not the TGF-b receptor has a role, and the
vascular cell type involved in calcineurin inhibitor–induced
renal arteriolar hyalinosis, has not been examined.
The TGF-b receptor consists of two subunits (I and II)
exhibiting a high affinity for one another, and TGF-b1
binding leads to receptor trans-phosphorylation and gene
transcription via the SMAD2/3-SMAD4 complex. The
immunophilins FK506-binding protein 12 (FKBP12) and
its related isoform 12.6 (FKBP12.6) bind the TGF-b1
receptor subunit I and prevent subunit phosphorylation in
the absence of a ligand.14 FKBP12/12.6 is then displaced
upon ligand binding to the receptor, allowing subunit
interaction/phosphorylation and downstream signaling to
occur.15 FKBP12 and 12.6 are also the intracellular targets of
TAC and we have shown that modulation of FKBP12/12.6
alters endothelial function, whereas direct inhibition of
calcineurin, the downstream target inhibited by the TAC/
FKBP12 complex, had no acute vascular effect.16–18
Given the role of FKBP12 in TGF-b receptor–mediated
signaling, as well as of TGF-b1 in the development of
arteriolar hyalinosis, we hypothesized that the TAC-mediated
activation of TGF-b receptors in endothelial cells causes renal
arteriolar hyalinosis by increasing matrix protein synthesis.
As both TAC and TGF-b1 have numerous other cellular
effects, we also used a genetic approach in mice to eliminate
the contribution of these other effects. We generated mice
lacking FKBP12 only in endothelial cells (FK12EC knockout
(KO)) to conditionally activate TGF-b receptors in an effort
to determine whether endothelial cell TGF-b receptor
activation is responsible for the development of renal
arteriolar hyalinosis.
RESULTS
TGF-b receptor activation in TAC-treated mice and
FK12EC KO mice
Mice treated for 1 week with TAC (10mg/kg/day) exhibited a
significant increase in aortic TGF-b1 protein expression, as
well as in aortic mRNA expression of angiotensin-converting
enzyme, angiotensinogen, and TGF-b1 (Figure 1a and b).
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Figure 1 | Tacrolimus (TAC) treatment or genetic deletion of FK506-binding protein 12 (FKBP12) from endothelial cells increases
SMAD2/3 activation. (a) Mice treated with TAC (10mg/kg/day, 1 week) had increased aortic expression of transforming growth factor
(TGF)-b1 compared with controls; however, FK12EC KO mice did not exhibit any changes in TGF-b1 expression. (b) Aortic mRNA levels of
angiotensin-converting enzyme (ACE), angiotensinogen (Agt), and TGF-b1 were increased significantly in TAC-treated mice but were not
changed in FK12EC knockout (KO) mice. Dotted line represents *Po0.05 vs. control. (c) SMAD2/3 phosphorylation was increased in aortas
from mice treated with TAC (10mg/kg/day) and FK12EC KO mice. Densitometry of TGF-b1 to actin or p-SMAD2/3 to SMAD2/3 as a
percentage of control; *Po0.05 vs. control. n¼ 8–11 mice per experimental group. C, controls; F, FK12EC KO.
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These increases were associated with TGF-b receptor
activation as demonstrated by increased SMAD2/3 phos-
phorylation (Figure 1c). Aortic SMAD2/3 phosphorylation
was also increased in mice treated with a lower concentration
of TAC (1mg/kg/day; Supplementary Figure 1 online). In
contrast, FK12EC KO mice did not exhibit an increase in
aortic TGF-b protein expression or angiotensin-converting
enzyme, angiotensinogen, or TGF-b1 mRNA expression
(Figure 1a and b). However, owing to the lack of inhibition
by FKBP12, aortic TGF-b receptor activation was signifi-
cantly increased in FK12EC KO mice compared with controls
(Figure 1c). To examine whether FK12EC KO mice, which
still have endothelial FKBP12.6 (Supplementary Figure 2A
online), might exhibit alterations in circulating levels of
TGF-b or angiotensin II, which can also activate SMAD2/3,19
we measured serum levels by enzyme-linked immunosorbent
assay (ELISA). FK12EC KO mice did not exhibit significant
changes in serum levels of TGF-b or angiotensin II
compared with control mice (Supplementary Figure 2B and
C online). In addition, there were no differences in aortic
calcineurin protein expression or activity in FK12EC
KO mice compared with controls (Supplementary Figure
3A and B online).
TGF-b receptor activation leads to renal arteriolar hyalinosis
Renal arteriolar hyalinosis appears as a pink, glassy area
encompassing the vascular wall in longitudinal sections of
histological examinations, and can be either focal, where only
certain parts of the blood vessel are affected, or concentric,
which affects the entire cross-section of the blood vessel.
TAC-treated mice exhibited a mild, but significant, increase
in renal arteriolar hyalinosis determined by both hematoxylin
and eosin, and Masson’s trichrome staining (Figure 2a). A
significant increase in renal arteriolar hyalinosis was also
evident in FK12EC KO mice as young as 12 weeks of age
(Figure 2b). In both models, the hyalinosis was focal in
nature, which is similar to that seen in renal allograft
recipients treated with TAC.
TGF-b receptor activation increases vascular matrix
protein expression
To examine whether the TGF-b receptor activation and renal
arteriolar hyalinosis was associated with increased produc-
tion of vascular matrix proteins, we measured collagen and
fibronectin expression in aortas of TAC-treated mice, as
well as FK12EC KO mice. Figure 3a demonstrates that
TAC significantly increased aortic collagen and fibronectin
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Figure 2 | Tacrolimus (TAC) treatment or genetic deletion of FK506-binding protein 12 (FKBP12) from endothelial cells caused
renal arteriolar hyalinosis. Hematoxylin and eosin (H&E) staining (top panels) and Masson’s trichrome staining (bottom panels)
reveal hyalinosis seen as the pink, glassy area indicated by the arrows in (a) TAC-treated mice (10mg/kg/day; 1 week) and in
(b) FK12EC knockout (KO) mice compared with controls. Images at  400 final magnification. Quantification of arteriolar hyalinosis
was determined using a scoring system previously described.7 n¼ 6 mice per experimental group; *Po0.05 vs. control.
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expression, which was also increased in FK12EC KO mice
compared with controls. TAC at 1mg/kg/day for 1 week also
increased aortic collagen and fibronectin expression (Supple-
mentary Figure 1 online). In addition, mRNA levels of
collagen and fibronectin were increased significantly in both
TAC-treated mice and FK12EC KO mice compared with
controls (Figure 3b).
Detrimental vascular effects of TAC are direct, independent
of calcineurin inhibition, and endothelium dependent
We next determined whether the TAC-induced changes were
a direct vascular effect by treating isolated aortas from
control mice with either vehicle, low-dose (1 mmol/l) TAC,
high-dose (10 mmol/l) TAC, or the calcineurin autoinhibitory
peptide (CAIP, 10 mmol/l) for 24 h. Both 1 mmol/l and
10 mmol/l TAC treatment significantly increased SMAD2/3
phosphorylation, as well as collagen and fibronectin expres-
sion (Figure 4). However, CAIP, used at a concentration that
inhibits calcineurin activity equal to that of TAC (Supple-
mentary Figure 4 online), had no effects on SMAD2/3
phosphorylation, collagen expression, or fibronectin expres-
sion (Figure 4).
To determine the vascular cell type crucial for the TAC-
induced SMAD2/3 signaling and matrix protein synthesis,
we removed the endothelium of isolated aortas and treated
them with TAC as above. Although it did not reach statistical
significance, endothelium removal tended to decrease
vascular collagen and fibronectin expression, suggesting that
the endothelium is a source of these proteins (Figure 5).
Denudation of control vessels did not increase SMAD2/3
phosphorylation and collagen and fibronectin expression.
Importantly, TAC treatment of endothelium-denuded vessels
also did not increase SMAD2/3 phosphorylation, collagen
expression, or fibronectin expression (Figure 5). Together,
these results demonstrate that TAC, independent of calci-
neurin inhibition, directly activates endothelial cell TGF-b
receptors, which causes collagen and fibronectin production.
Inhibition of TGF-b receptor activation prevents vascular
matrix protein expression
To further examine whether TGF-b receptor activation
mediates the increase in vascular collagen and fibronectin,
we co-treated isolated aortas with TAC and the TGF-b
receptor inhibitor SB-505124.20 SB-505124 prevented the
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Figure 3 | Tacrolimus (TAC) treatment or genetic deletion of FK506-binding protein 12 (FKBP12) from endothelial cells increased
vascular matrix protein production. (a) Increased protein levels of collagen and fibronectin in aortas from mice treated with TAC
(10mg/kg/day) and FK12EC knockout (KO) mice. Densitometry of collagen and fibronectin to actin as a percentage of control; *Po0.05
vs. control. (b) Increased mRNA levels of collagen and fibronectin in aortas from mice treated with TAC (10mg/kg/day) and FK12EC KO
mice. n¼ 8–11 mice in each group. Dotted line represents *Po0.05 vs. control. C, controls; F, FK12EC KO.
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increase in SMAD2/3 phosphorylation and collagen and
fibronectin expression induced by TAC (Figure 6).
DISCUSSION
Although most renal transplant recipients exhibit renal
arteriolar hyalinosis, the molecular mechanisms by which
this develops are unknown. To test the hypothesis that
endothelial cell TGF-b receptor activation has a central role
in the development of calcineurin inhibitor–induced renal
arteriolar hyalinosis, we compared findings in TAC-treated
mice with mice that we generated, which lack FKBP12 in
endothelial cells resulting in constitutive TGF-b receptor
activation without increased TGF-b or angiotensin II levels.
Our findings reveal that TAC, through its known effects of
increasing TGF-b1 levels,11–13 increased SMAD2/3 activation,
vascular matrix protein production, and renal arteriolar
hyalinosis (Figure 7). The TAC-induced increase in SMAD2/3
activation and matrix protein production was calcineurin
independent, but did depend on the endothelium and TGF-b
receptor activation. In FK12EC KO mice, circulating TGF-b
or angiotensin II levels were not increased; however, these
mice exhibited a similar increase in SMAD2/3 activation,
vascular matrix protein production, and renal arteriolar
hyalinosis. Although the extent of hyalinosis in the renal
arterioles of both models was relatively mild and the lumen
diameter was not compromised, the presence of this
arteriolopathy after 1 week of TAC treatment and in young
FK12EC KO mice likely represents the early stages of this
progressive disease. Nevertheless, the similar findings suggest
that endothelial TGF-b receptor activation is sufficient to
induce vascular matrix protein synthesis and renal arteriolar
hyalinosis.
Animal models of calcineurin inhibitor toxicity that
exhibit renal arteriolar hyalinosis include rats treated with
ciclosporin or TAC, as well as sodium-depleted mice
administered with these calcineurin inhibitors.7,8,11,21–23
TGF-b1 and angiotensin II were found to be crucial for
hyalinosis development in these models, as inhibition of
TGF-b1, sodium repletion, or blockade of the angiotensin II
type 1 receptor prevented the development of arteriolar
hyalinosis. In addition, lowering of blood pressure with
hydralazine/furosemide alone had no effect on hyalinosis.
Angiotensin II has been shown to increase TGF-b1, SMAD2/
3 phosphorylation, and collagen I mRNA levels, and these
effects were mediated by both the TGF-b receptor and the
angiotensin II type 1 receptor.6,10 The convergence of these
two pathways on SMAD2/3, in addition to another report
showing that knockdown of SMAD3 prevents the induction
of collagen I mRNA,10 suggests that SMAD3 activation is
important in the development of arteriolar hyalinosis. These
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Figure 4 | Tacrolimus (TAC) treatment, but not calcineurin inhibition, increased SMAD2/3 activation and vascular matrix protein
production in isolated aortas. TAC increased SMAD2/3 phosphorylation and protein levels of collagen and fibronectin in aortas isolated
from control mice, whereas the calcineurin autoinhibitory peptide (CAIP) had no effect. n¼ 8–11 mice per experimental group.
Densitometry of p-SMAD2/3 to SMAD2/3 or collagen and fibronectin to actin as a percentage of control; *Po0.05 vs. control.
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findings were supported in our TAC-treated mice, as these
mice exhibited increased TGF-b1 and angiotensin II, TGF-b
receptor activation, collagen and fibronectin production, and
renal arteriolar hyalinosis. Mice treated with TAC at 1mg/kg/
day exhibited increased vascular SMAD2/3 phosphorylation
and collagen and fibronectin expression. Even though this
dose in mice isB10 times higher than doses administered to
patients, it achieves plasma levels comparable to that of
treated patients.24 Treatment of mice with 10mg/kg/day,
which represents a nephrotoxic dose likely resulting in whole
blood and plasma levelsB5–10 times higher than those seen
clinically,24,25 exacerbated these effects. The TAC-induced
increases in SMAD2/3 activation and collagen and fibronec-
tin production were a direct vascular effect, as these same
effects were observed in isolated blood vessels treated with
TAC. The in vitro concentrations of 1 mmol/l and 10 mmol/l
TAC used in our study correspond to B800 ng/ml and
B8000 ng/ml, respectively, and are much higher than the
ideal whole blood levels of 10–30 ng/ml in patients. Although
these doses were shown to inhibit T-cell proliferation
and cytokine production in immune cells in vitro and are
within the range of effective concentrations (1 nmol/
l–25 mmol/l) for in vitro use, results from our in vitro studies
may not reflect what is occurring in vivo.26–28 Nevertheless,
the detrimental vascular effects could be prevented by
removing the endothelium or inhibiting TGF-b receptor
activation.
Despite convincing evidence that TGF-b1 and angiotensin
II have important roles in the development of arteriolar
hyalinosis in these experimental models, our FK12EC KO
mice did not exhibit alterations in serum or vascular mRNA
levels of either TGF-b1 or angiotensin II. However, complete
deletion of endothelial cell FKBP12, resulting in constitutive
activation of TGF-b receptors and arteriolar hyalinosis,
suggests that SMAD2/3 activation has a critical and sufficient
role. Other potential mediators of arteriolar hyalinosis
include osteopontin and PAI-1.6,8,22 Both TAC and ciclos-
porin treatment increase osteopontin gene expression in
mice, as well as in human proximal tubular epithelial cells,
and osteopontin expression is increased early in the
hyalinosis/fibrotic process.6,22,29 In addition, osteopontin-
deficient mice exhibit reduced arteriolar hyalinosis and
interstitial collagen deposition in response to low sodium
plus ciclosporin treatment.30 However, the induction of
osteopontin and PAI-1 expression by calcineurin inhibitors
are mediated by increases in TGF-b1 signaling, which
supports our hypothesis that TGF-b receptor activation
mediates the elevation of these fibrogenic factors.8,24
The immunosuppressive drug sirolimus also increases
TGF-b1 levels, binds FKBP12, and increases SMAD2/3
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Figure 5 |Removal of endothelium prevented the tacrolimus (TAC)-induced increase in SMAD2/3 activation and vascular
matrix protein production in isolated aortas. Denuding of endothelial cells prevented the TAC-induced increase in SMAD2/3
phosphorylation and protein levels of collagen and fibronectin in aortas isolated from control mice. n¼ 8–11 mice per experimental
group. Densitometry of p-SMAD2/3 to SMAD2/3 or collagen and fibronectin to actin as a percentage of control; *Po0.05 vs. control.
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activation;31 however, studies have shown that nephrotoxicity
is reduced and the progression of chronic allograft lesions is
decreased in renal allograft recipients.32 Similar to TAC,
sirolimus binds FKBP12/12.6 and leads to TGF-b receptor
activation; however, the sirolimus/FKBP12 complex inhibits
the kinase mammalian target of rapamycin (mTOR) instead
of the phosphatase calcineurin. mTOR has a major role in cell
proliferation, inhibits apoptosis, and may contribute to
vascular matrix protein synthesis. Interestingly, TAC increases
mTOR in vascular smooth muscle cells, and this is associated
with increased vascular collagen I expression.33 Thus,
inhibition of mTOR, in addition to TGF-b receptors, may
prevent the development of arteriolar hyalinosis in TAC-
treated allograft recipients.
As ciclosporin and TAC both increase TGF-b1 and
angiotensin II levels, inhibit calcineurin, and cause renal
arteriolar hyalinosis, it remained unknown whether SMAD2/
3 activation and/or calcineurin inhibition is the crucial
mediator. If calcineurin inhibition is the pathogenetic
mechanism, then one would expect calcineurin KO mice to
exhibit renal arteriolar hyalinosis. Gooch et al.34 reported
that calcineurin Aa KO mice exhibit increased renal
expression of fibronectin and renal arteriolar hyalinosis.
However, the degree of arteriolar hyalinosis was much lower
than that seen in ciclosporin-treated mice, and a major
confounding factor is that TGF-b1 levels were increased
significantly in calcineurin Aa KO mice. Calcineurin Ab KO
mice, which do not exhibit renal arteriolar hyalinosis, did not
have increased levels of TGF-b1 compared with control mice.
We addressed the role of calcineurin using a pharmacological
approach and hypothesized that if calcineurin inhibition is
responsible for the increased matrix protein synthesis then we
would expect CAIP to increase collagen and fibronectin
expression in isolated vessels. However, the peptide had no
effect. Thus, calcineurin inhibitor–induced activation of TGF-
b receptors mediates the increased matrix protein production
and the development of renal arteriolar hyalinosis indepen-
dent of calcineurin inhibition. Unlike TAC, ciclosporin does
not bind FKBP12 but, similar to TAC, increases TGF-b1 and
angiotensin II levels, which would lead to TGF-b receptor
activation and displacement of FKBP12, resulting in SMAD2/
3 phosphorylation and collagen and fibronectin production.
Whether this pathway is responsible for the development of
ciclosporin-induced arteriolar hyalinosis remains to be
determined.
Finally, the vascular cell type that initiates the process of
hyalinization remained unknown. Previous studies have
shown that endothelial cells can produce and secrete collagen
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and fibronectin, which would diffuse to and injure the
interstitium and smooth muscle cells.35–39 This selective
injury of medial smooth muscle cells is then replaced by
hyaline deposits, resulting in a focal pattern consistent with
that observed in calcineurin inhibitor toxicity. In contrast,
hypertension and diabetes result in arteriolar hyalinosis that
is concentric in nature, which may result from increased
vascular permeability leading to subendothelial hyaline
deposition. Our findings that endothelial cell–specific TGF-
b receptor activation (FK12EC KO mice) leads to vascular
matrix protein production and arteriolar hyalinosis, and that
removal of the endothelium prevents the TAC-induced
increase in SMAD2/3 activation and matrix protein produc-
tion support the notion that endothelial cells initiate the
hyalinization process induced by TAC.
In conclusion, these are the first data to demonstrate that
endothelial cell TGF-b receptor activation is sufficient to
cause renal arteriolar hyalinosis. Although some of these
studies were conducted in mouse aortas, it is likely that these
signaling pathways and mechanisms also occur in renal
arterioles. Nevertheless, endothelial cell SMAD2/3 activation
appears to be the major initiator in the pathogenesis of renal
arteriolar hyalinosis, and future immunosuppressive drugs
that do not increase TGF-b1 levels or lead to TGF-b receptor
activation should be developed for renal allograft recipients.
MATERIALS AND METHODS
Animals
Wild-type male C57Bl/6J mice (The Jackson Laboratory, Bar
Harbor, ME) were treated with daily intraperitoneal injections of
either low-dose TAC (1mg/kg/day), high-dose TAC (10mg/kg/day),
or vehicle (dimethyl sulfoxide, o1% final concentration) for 1
week. FK12EC KO mice were generated by crossing Tie2-Cre C57Bl/
6J mice (The Jackson Laboratory) with mice containing lox P sites
flanking either side of FKBP12 (generously provided by Dr Susan
Hamilton, Baylor College of Medicine).40 Wild-type male C57Bl/6J
mice served as controls, and all animals were studied at 10–12 weeks
of age. All procedures were approved by the Texas A&M Health
Science Center/Scott & White Memorial Hospital Institutional
Animal Care and Use Committee in accordance with the NIH Guide
for the Care and Use of Laboratory Animals.
Confirmation of FK12EC KO
Cardiac endothelial cells were isolated from control and FK12EC KO
mice, and protein levels of FKBP12 and FKBP12.6 were measured
using a LI-COR Odyssey (see below) and an anti-FKBP12/12.6
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) with b-actin
serving as a loading control.
Enzyme-linked immunosorbent assays
Plasma (50 ml) was used in the ELISAs for both TGF-b1 and
angiotensin II according to the manufacturer’s protocol (Phoenix
Pharmaceuticals, Burlingame, CA).
Histology
Control and FK12EC KO mice were anesthetized with isoflurane and
killed by exsanguination. Sections (3–5 mm thick) from isolated
kidneys were obtained on a microtome, deparaffinized, and stained
with either hematoxylin and eosin or Masson’s trichrome. Scoring
for hyalinosis was performed as described previously.30 In brief, a
blinded reviewer scored 25 fields per section for both the left and
right kidneys of each mouse using a 1–4 scale (1¼ hyalinosis evident
in o10% of the field, 2¼ 10–25%, 3¼ 25–50%, and 4¼450%).
Quantitative real-time PCR
Quantitative real-time PCR was performed to analyze mRNA
expression in endothelium-intact aortas from control and FK12EC
KO mice. Gene expression was measured using a Mouse Endothelial
Cell Biology RT2 Profiler PCR Array and was performed according
to the manufacturer’s protocol (SABiosciences, Frederick, MD).
Results are expressed as fold change compared with control, with an
increase or decrease of twofold considered statistically significant.
Immunoblotting
Endothelium-intact and endothelium-denuded aortas were pro-
cessed and imaged as described previously.16–18 Some aortas isolated
from control mice were denuded of endothelial cells by repeatedly
injecting air through the aorta, treated with CAIP (10mmol/l, 30min;
Calbiochem, Gibbstown, NJ), or treated with the TGF-b receptor
inhibitor SB-505124 (10mmol/l, 30min; Sigma, St Louis, MO),
followed by treatment with TAC (1 or 10mmol/l, 24 h). Primary
antibodies for TGF-b1, phospho-SMAD2/3, SMAD2/3, collagen type
I, fibronectin, calcineurin, and b-actin were used, followed by
secondary antibodies consisting of anti-mouse, anti-rabbit, or anti-
goat IgGs conjugated to either Alexa-Fluor 680 or IR800Dye
(LI-COR Biosciences; Lincoln, NE).
Endothelial cell
TAC
CaN
FKBP
12/12.6
FKBP
12/12.6
TAC TGF-β1
TGF-β receptor
pSMAD2/3
SMAD4
Collagen, fibronectin
Smooth muscle cell
Arteriolar
hyalinosis
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Figure 7 |Diagram of molecular mechanisms involved in
the development of renal arteriolar hyalinosis. Increased
transforming growth factor (TGF)-b receptor activation leads to
SMAD2/3 activation and increased production of collagen and
fibronectin, which are secreted to the smooth muscle cell causing
injury and hyalinosis. CaN, calcineurin; CsA, ciclosporin; FKBP,
FK506-binding protein; TAC, tacrolimus.
864 Kidney International (2012) 82, 857–866
or ig ina l a r t i c l e VL Chiasson et al.: TGF-b receptor activation and hyalinosis
Calcineurin activity assay
Isolated aortas from FK12EC KO and control mice, as well as
isolated control aortas treated with TAC or CAIP, were homogenized
in the presence of protease and phosphatase inhibitors. Vascular
homogenates (250 mg of protein) were used to measure calcineurin
activity, which was performed using a Calcineurin Assay Kit
according to the manufacturer’s protocol (Calbiochem).
Statistical analyses
Results are presented as mean±s.e.m. For serum TGF-b1 and
angiotensin II levels, the values obtained from the ELISA were
compared with the mean of the controls in each trial and expressed
as a percentage of controls. For multiple comparisons between TAC-
treated and control mice, an analysis of variance was used, followed
by the Student–Newman–Keul post hoc test. The two-tailed Student’s
t-test was used to compare variables between FK12EC KO and
controls. The significance level was set at 0.05.
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SUPPLEMENTARY MATERIAL
Figure S1. Tacrolimus (TAC) treatment increased TGF-b receptor
activation and vascular matrix protein production.
Figure S2. Mice lacking FKBP12 in endothelial cells do not exhibit
changes in serum TGF-b or angiotensin II.
Figure S3. No differences in vascular calcineurin expression or
activity in FK12EC KO mice.
Figure S4. Similar inhibition of aortic calcineurin activity between
tacrolimus (TAC) and the calcineurin autoinhibitory peptide (CAIP).
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